联合用药治疗耐碳青霉烯铜绿假单胞菌感染的研究进展  

Progress in Combination Therapy to Infection of Carbapenem-Resistant Pseudomonas aeruginosa

作　　者：杨德青[1,2] 倪文涛[3] 江学维[2] 王瑾[2] 王睿[2] 于白雪[2] YANG De-qing NI Wen-tao JIANG Xue-wei WANG Jin WANG Rui YU Bai-xue(School of Phar- macy and Chemistry, Dali University, Dali 671000, China Chinese People＇ s Liberation Army General Hospital, Center ofMedi- cine/Medical Devices Clinical Research Department of Respiratory Diseases, Beijing 100853, China)

机构地区：[1]大理大学药学与化学学院,云南大理671000 [2]中国人民解放军总医院药物/器械临床试验中心,北京100853 [3]中国人民解放军总医院呼吸科,北京100853

出　　处：《中国药学杂志》2017年第14期1208-1211,共4页Chinese Pharmaceutical Journal

基　　金：十二五国家重大科技专项资助(2012ZX09303004-002)

摘　　要：耐碳青霉烯类铜绿假单胞菌(carbapenem-resistant Pseudomonas aeruginosa,CRPA)已有在医院院内爆发流行的趋势,治疗失败率和病死率高,有效的单用抗菌药物非常有限,往往建议联合用药治疗CRPA感染。笔者就联合用药治疗CRPA感染的体内外效应及临床研究方面进行综述,以全面掌握联合用药治疗CRPA感染的研究进展,为临床合理使用联合方案治疗CRPA感染提供一定的试验基础。The outbreak of carbapenem-resistant Pseudomonas aeruginosa has been continuously reported in hospitals worhtwide. The infection caused by carbapenem-resistant Pseudomonas aeruginosa increased the therapy failure and mortality, the effective antibi- otics against carbapenem-resistant Pseudomonas aeruginosa are limited, and combination therapy is often recommended to treat CRPA infection. To fully master the advance on combination therapy of CRPA infection, and provide a theoretical basis for the rational use of the combination therapy, this article reviewed the synergistic effect in vitro or in vivo and clinical study of antimicrobial agents treating CRPA infection.

关 键 词：耐碳青霉烯铜绿假单胞菌 联合效应 联合用药 治疗 

分 类 号：R969.3[医药卫生—药理学]